PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?
Pfizer VS Moderna Third Quarter Earnings And Revenue
avatar
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.
2022-12-10 10:30

Pfizer Inc (NYSE: PFE). is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. The business was founded in 1849. Pfizer is well recognized as an industry leader in biopharmaceutical research for developing the COVID-19 vaccine.PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?
Moderna, Inc. (NASDAQ: MRNA) is a Cambridge, Massachusetts-based pharmaceutical and biotechnology business specializing in mRNA vaccines and other RNA treatments. The Moderna COVID-19 vaccine, sometimes known as Spikevax, is the only commercially available item for the company.

Pfizer and Moderna are the two largest pharmaceutical corporations in the United States. If you want to add one to your portfolio, this article will study and compare the two to make your decision easier.

Pfizer VS Moderna Third Quarter Earnings And Revenue
MODERNA:
Specifically, because of a reduction in sales of the Company's COVID-19 vaccines, total revenue for the third quarter of 2022 was $3.4 billion as opposed to $5.0 billion at the same time in 2021. Compared to the same period in 2021, product sales for the third quarter of 2022 were $3.1 billion, a 35% decrease. This decline was primarily attributable to lower sales volume brought on by the timing of market authorizations for our COVID-19 bivalent boosters and the ensuing manufacturing ramp-up.

The business reported $1.04 billion in net profits for the quarter, a 68% decrease from the prior year. The Covid vaccination is expected to generate between $18 billion and $19 billion in revenue for Moderna this year. This is attributed to supply chain issues that delayed the delivery of several vaccines until 2023.

PFIZER: Due to waning demand for its Covid vaccines abroad, Pfizer saw a 6% decline in third-quarter global revenue to $22.6 billion from the same period in 2017. In the third quarter, the company sold its vaccine for $4.4 billion globally, a 66% decrease from the same period in 2021. It anticipates earnings per share of $6.40 to $6.50 for the year, up from its previous forecast of $6.30 to $6.45. Pfizer's net income for the third quarter was $8.6 billion, up 6% over the same period last year.

Pfizer VS Moderna P/E Ratio
From a value standpoint, the P/E ratio can assist us in evaluating which of the two is less expensive. Pfizer Inc. (NYSE: PFE) has a trailing 12-month P/E of 7.71X, while the Large Cap Pharmaceuticals industry has a P/E of 14.37X.

Moderna, Inc. (NASDAQ: MRNA) has a trailing-12-month P/E of 6.48X, while the Medical - Biomedical and Genetics industry has a P/E of 18.99X.

According to our research, Moderna stocks are significantly less expensive than Pfizer because they have a lower P/E ratio. A high price-to-earnings ratio indicates that the company is overvalued.

Pfizer Vs Moderna In Dividends
Pfizer's
(NYSE: PFE) Trailing twelve months (TTM) dividend payout is $1.60 as of December 08, 2022. Pfizer's current dividend yield is 3.22% as of December 8, 2022.

Pfizer pays dividends and currently has a higher dividend yield of 3.22% over the sector average of 1.57%. As a result, PFE stock can provide you with income while expanding your investment.

Moderna(NASDAQ: MRNA) pays no dividends.

Pfizer Vs Moderna In Developing Future Projects
Pfizer
(NYSE: PFE) has a more diverse business. Pfizer plans to launch five "new vaccines" and two oncology and immuno-inflammation medicines next year.

Moderna (NASDAQ: MRNA) has not made any public statement about future projects. Moderna's revenues are currently primarily tied to its COVID-19 products.

Based on the above analysis, Pfizer (PFE) appears to be a more profitable stock to add to your portfolio. Pfizer stock will be profitable in the long run, from third-quarter earnings and revenues to creating future ventures. Pfizer is our experts' choice here over Moderna.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2022-12-10 10:30

avatar
About the Author
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Levi Strauss' Bold Gambit: Is the Denim Icon's DTC Shift Enough to Weather the Storm?
Levi Strauss & Co. boasts a strong quarter with direct-to-consumer growth and innovative fashion, but can it navigate the choppy waters of the retail market?
By Alfonso | 3 months ago

Amazon's Bold Counterattack: Introducing the China-Direct Discount Section
As competition heats up, Amazon unveils a daring new strategy to offer unbeatable prices and direct shipping from China.
By Alfonso | 3 months ago

Tesla's Legal Challenges: Facing the Music on Autopilot Misrepresentation
Court ruling intensifies scrutiny on Tesla's self-driving claims.
By Alfonso | 5 months ago

Netflix's Ad-Supported Triumph: A New Era in Streaming
Surpassing 40 million users, Netflix’s ad-supported plan redefines the streaming landscape.
By Alfonso | 5 months ago

Tesla Stock (TSLA): Look Who's Back!
I’m cautiously optimistic but I’m at the point where I need to see it to believe it.
By Mike Sakuraba | 5 months ago

2 Earnings To Pay Attention to Next Week
Since big tech is the theme, you probably know what I have my eyes on for next week.
By Mike Sakuraba | 5 months ago

2 Stocks to Watch Below $10
Here are two stocks that are currently less trading in the single digits that I believe have some relative upside from their current prices.
By Mike Sakuraba | 5 months ago

Looking Ahead to Tesla's Earnings: What Can We Expect?
Is there any stock that has been more talked about than Tesla (NASDAQ: TSLA) as of late? It’s a company that is always in the spotlight but the stock is under some heavy scrutiny this year and deservedly so.
By Mike Sakuraba | 5 months ago